Company

ABOUT US


BioCision is a life science research and development company that develops products and solutions for process standardization throughout the healthcare industry through the application of advanced thermal regulation principles and technologies. The intuitive design and interconnectivity of BioCision products enables researchers, clinicians and manufacturers to protect the integrity of temperature-sensitive therapeutics, biological samples, and biomaterials.  By comprehensively addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.

 

 

 


MANAGEMENT TEAM ↑ top

Rolf Ehrhardt, MD, PhD

President and Chief Executive Officer

Dr. Rolf Ehrhardt brings more than 25 years of experience in leadership and innovation in life science research, products, and pre-clinical and clinical drug development. Prior to growing BioCision into the leading provider of temperature-sensitive sample handling solutions, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech, now Anesiva. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery/validation and development of immunotherapeutics at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his medical and doctoral degrees with distinction from the Technical University of Munich, Germany.

Hugh Douglas

Chief Operating Officer

Mr. Douglas most recently led Bridge4Bio, LLC, a global business consulting group. Previously, he was managing director and president of Hoefer, Inc., a part of Harvard Bioscience. Mr. Douglas was also vice president of the West Coast operations for Amersham Biosciences, now a part of GE Healthcare. He has been involved in start-ups, acquisitions and spin-outs and has broad experience in managing companies for growth and success. Mr. Douglas holds a B.A. from the University of California, Berkeley and earned his M.B.A. from Golden Gate University.

Ron DiNocco

Chief Financial Officer

Mr. DiNocco joined Biocision in 2008 managing corporate finance development with responsibility for long term capital strategy and investor relations. From 2000-2008 he served multiple leadership roles at Akiva Corporation, including CFO and CEO, while achieving global expansion through new customer and government relationships. During this time, Ron was able to successfully close an institutional Series A round and negotiated the acquisition of a division of O'Reilly and Associates. He holds a bachelor's degree from Babson College and has also completed International Business studies at the University of Monash in Australia. Mr. DiNocco serves on the board of Tech Coast Angels and is an active supporter of early stage companies.

Michelle Nemits

Chief Commercial Officer

Ms. Nemits joined BioCision in early 2008, with almost 20 years of experience in sales of laboratory products and services. Before joining BioCision she was director of business development at VWR International LLC, a global laboratory supply distributor, where she forged partnerships with global biopharmaceutical customers with complex supply chain requirements. During her 11-year tenure at VWR, Ms. Nemits held various sales and management positions in the global accounts division. Prior to joining VWR, she held sales and marketing positions with Wheaton Science Products of Millville, New Jersey, and Ishihara Sangyo Kaisha, a Japanese chemical manufacturer with U.S. sales operations based in the San Francisco Bay Area.

Samuel Kent

Vice President, Global Sales

Mr. Kent joined BioCision in early 2013, with over 13 years of experience in sales of a diverse portfolio of laboratory products and services. Prior to joining BioCision, Samuel served in multiple senior roles at Thermo Fisher Scientific and Parker Hannifin including Commercial Manager North America and Global Business Development Manager. In these positions, he was instrumental in expanding corporate presence and commercial success in the clinical chemistry, academic research, pharmaceutical, food and beverage safety and the analytical environmental markets. Samuel graduated with his Masters of Business Administration from Colorado State University and his Bachelor of Science from Northern Michigan University.

Brian Schryver

Vice President, Product Development

Mr. Schryver co-founded BioCision in 2007, after a 25-year career in molecular biological research and development. He has extensive experience developing instruments and tooling for the life science field. Prior to co-founding BioCision, Mr. Schryver was a scientist at CFD Therapeutics Inc. and worked in topical formulation and assay development at Corgentech, now Anesiva. Mr. Schryver also was involved in preclinical development and biomarker research at SUGEN, and discovery research at Syntex.

Maria Thompson, PhD

Scientific Affairs

Dr. Maria Thompson has a background in molecular genetics and over 15 years of experience in pharmaceutical and diagnostics research and development. She has held a variety of roles including Head of Genome Wide Screening for Type 2 diabetes, Six Sigma Black Belt, Principal Consultant, and Head of Scientific Affairs, as well as running a private consulting company providing scientific and technical advisory services to clients across the life science industry. Dr. Thompson holds a BSc in Genetics and a PhD in Molecular and Cellular Biochemistry from the Royal London School of Medicine, UK.

BOARD OF DIRECTORS ↑ top

Rolf Ehrhardt, MD, PhD

President and Chief Executive Officer

Dr. Rolf Ehrhardt brings more than 25 years of experience in leadership and innovation in life science research, products, and pre-clinical and clinical drug development to BioCision. Prior to growing BioCision into the leading provider of bench-top sample handling solutions, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech, now Anesiva. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery/validation and development of immunotherapeutics at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his medical and doctoral degrees with distinction from the Technical University of Munich, Germany.

Paul Nowak

CEO of Biotix Holdings

Mr. Nowak joined Biotix Holdings in April 2007. Prior to that, he was the Chief Operating Officer of Symyx Technologies, a Silicon Valley manufacturer of high-throughput robotics and developer of software applications for R&D. He spent the majority of his career (26 years) at VWR International, a global distributor of laboratory supplies where he held many positions during his tenure, including CEO and President. Mr. Nowak was one of the key leaders that transformed VWR into a $2.8 billion company.

Blair W. Stewart

JD – Legal Advisor

Mr. Stewart, a former corporate partner of Wilson, Sonsini, Goodrich & Rosati, has practiced corporate, securities and business law in Silicon Valley for more than 35 years, offering strategic business and legal advice to emerging biotechnology and high technology companies. He practiced at Wilson, Sonsini Goodrich & Rosati from 1976 to 2001, becoming a partner in 1983. Since 2001 he has conducted a private legal practice as well as co-founding an angel-investor and venture-capital-backed biotechnology company, now in clinical trials. He has advised both for-profit and non-profit companies in regulatory and corporate governance, and is experienced in public and private financings, mergers and acquisitions, intellectual property and licensing, and domestic and international joint ventures. Mr. Stewart holds a Doctor of Jurisprudence from Stanford Law School and a Bachelor of Science from the United States Naval Academy.

Brian Schryver

Vice President, Product Development

Mr. Schryver co-founded BioCision in 2007, after a 25-year career in molecular biological research and development. He has extensive experience developing instruments and tooling for the life science field. Prior to co-founding BioCision, Mr. Schryver was a scientist at CFD Therapeutics Inc. and worked in topical formulation and assay development at Corgentech, now Anesiva. Mr. Schryver also was involved in preclinical development and biomarker research at SUGEN, and discovery research at Syntex.

Hugh Douglas

Chief Operating Officer

Mr. Douglas most recently led Bridge4Bio, LLC, a global business consulting group. Previously, he was managing director and president of Hoefer, Inc., a part of Harvard Bioscience. Mr. Douglas was also vice president of the West Coast operations for Amersham Biosciences, now a part of GE Healthcare. He has been involved in start-ups, acquisitions and spin-outs and has broad experience in managing companies for growth and success. Mr. Douglas holds a B.A. from the University of California, Berkeley and earned his M.B.A. from Golden Gate University.

ADVISORY BOARD↑ top

Lori Kunkel, MD

Principal at D2D, LLC

Advisory Board Chair

Dr. Kunkel brings extensive experience in developing and commercializing oncologic and immunologic therapies, with over 20 years of executive responsibilities in industry including clinical, regulatory, medical affairs and licensing. As chief medical officer at Pharmacyclics, she was instrumental in achieving breakthrough designation for the company’s lead product, ibrutinib. Previously, Dr. Kunkel spent ten years in academic and clinical research and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles.

Lee Buckler, JD

Founder and Managing Director of the Cell Therapy Group

Mr. Buckler is focused on the cell therapy and regenerative medicine industries, consulting on business development strategies, competitive intelligence, market research and analysis, deal-making, marketing and communications, and sales-lead generation. He founded Cell Therapy News and Cell Therapy Blog, and serves on the editorial board of the journals BioProcess International and Regenerative Medicine. Before transitioning to biotech, Mr. Buckler earned a law degree from University of British Columbia and was a practicing commercial attorney.

Scott Burger, MD

Principal at Advanced Cell & Gene Therapy

As principal at Advanced Cell & Gene Therapy, Dr. Burger consults on the development and commercialization of cell therapy, gene therapy, and tissue-engineered products, providing expert assistance in due diligence and strategic partnering, GMP/GTP manufacturing, process development, characterization and comparability, and regulatory affairs. Previously, Dr. Burger spent eight years directing the University of Minnesota Cell Therapy Clinical Laboratory, a GMP laboratory that manufactures cell therapy and gene therapy products for clinical trials and transplantation, and served as VP of R&D at Merix Bioscience, a dendritic cell therapy company.

Jon Rowley, PhD

Chief Executive and Technology Officer of RoosterBio, Inc.

Dr. Rowley has made it his personal goal to make significant contributions to the commercial translation of living cellular technologies. He holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 30 peer reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Dr. Rowley most recently spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy CMO business.

Who is using CoolProducts.


What are our customers saying about CoolProducts.


Download our Catalog.


Product Overview.


The following designations are trademarks owned by BioCision, LLC:

BioCision®
Standardizing Samples®
BioT™
CoolBox™
CoolCell®
CoolProbe™
CoolRack®
CoolSink®
CoolStation™
CoolSystem™
CoolProducts™
ThermalTray™
TruCool®
SASA™
ScientistsAgainstSampleAbuse™